Streetbeat News

NXGL

NEXGEL, Inc.

Industry

Medical - Instruments & Supplies

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.

Open

4.50

Mkt cap

32M

Volume

422K

High

4.82

P/E Ratio

-7.14

52-wk high

4.82

Low

4.31

Div yield

N/A

52-wk low

1.84

NEXGEL, Inc. held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included CEO Adam Levy and CFO Adam Drapczuk.

Portfolio Pulse from

November 14, 2024 | 4:15 am

NEXGEL reported a record third quarter 2024 revenue of $2.94 million, marking a 141% year-over-year increase and a 104% sequential rise. The growth was driven by a 99% increase in branded consumer products and a 103% rise in contract manufacturing.

Portfolio Pulse from

November 13, 2024 | 10:00 pm

NEXGEL, Inc. announced a $2,000,000 registered direct offering involving the sale of 727,272 shares of common stock and warrants for 363,636 shares. The offering price is $2.75 per share, with warrants exercisable at $4.25 per share for five years.

Portfolio Pulse from

November 11, 2024 | 10:45 pm

Several healthcare stocks experienced significant price movements during Thursday's intraday session. Notable gainers included TransCode Therapeutics, Vaccinex, and NexGel, while Gritstone Bio and 10x Genomics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 4:31 pm

NEXTGEL shares rise as the company anticipates a year-over-year increase in Q3 preliminary revenue.